Halozyme Therapeutics | HALO - Ebitda

Prix De L'Action
63.43
Variation Quotidienne
0.16 0.25%
Mensuellement
-10.21%
Annuel
-2.66%
Q1 Prévisions
61.53




Ebitda Changement Date
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
Agios Pharmaceuticals USD -115.49M 10.3M 2025-09
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amarin USD 12.54M 28.57M 2025-06
Amgen USD 5.14B 775M 2025-12
Baxter International USD 426M 36M 2025-09
Cara Therapeutics USD -2.39M 3.16M 2025-03
Cytokinetics USD -277.18M 169.36M 2025-09
DBV Technologies USD -33.48M 5.55M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Halozyme Therapeutics USD 21.9M 226.34M 2025-12
Intrexon USD -24.7M 2.92M 2024-06
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
MannKind USD 17.92M 8.17M 2025-09
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Pfizer USD 6.08B 351M 2025-09
Rigel Pharmaceuticals USD -4.17M 798K 2023-09
United Therapeutics USD 379.5M 83.4M 2025-12
Vanda Pharmaceuticals USD -8.31M 2.37M 2024-12